Ciprofloxacin 500Mg Tablet + Doxycycline 100Mg Tablet + AV7909

Phase 2Completed
0 watching 0 views this week Active
44
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anthrax

Conditions

Anthrax

Trial Timeline

Aug 12, 2019 → Mar 19, 2020

About Ciprofloxacin 500Mg Tablet + Doxycycline 100Mg Tablet + AV7909

Ciprofloxacin 500Mg Tablet + Doxycycline 100Mg Tablet + AV7909 is a phase 2 stage product being developed by Emergent BioSolutions for Anthrax. The current trial status is completed. This product is registered under clinical trial identifier NCT04067011. Target conditions include Anthrax.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04067011Phase 2Completed

Competing Products

15 competing products in Anthrax

See all competitors
ProductCompanyStageHype Score
Cipro (Ciprofloxacin, BAYQ3939)BayerPre-clinical
20
AV7909 Full Dose (0.5 mL) + AV7909 Half Dose (0.25 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)ICON plc.Phase 2
49
AV7909 + BioThraxEmergent BioSolutionsPhase 3
69
AV7909 + BioThraxEmergent BioSolutionsPhase 2
44
AIGIVEmergent BioSolutionsPre-clinical
15
CYFENDUSEmergent BioSolutionsPre-clinical
15
BioThrax + CiprofloxacinEmergent BioSolutionsPhase 2
44
BioThrax + AV7909 Formulation 1 + AV7909 Formulation 2 + AV7909 Formulation 3 + AV7909 Formulation 4 + ControlEmergent BioSolutionsPhase 1
25
AVP-21D9 + PlaceboEmergent BioSolutionsPhase 1
25
AIGIVEmergent BioSolutionsPre-clinical
15
AIGIV 3.5 mg/kg + Gamunex 90 mg/kg + AIGIV 7.0 mg/kg + Gamunex 180 mg/kg + AIGIV 14.0 mg/kg + Gamunex 360 mg/kgEmergent BioSolutionsPhase 1/2
33
AVA + Ad4-PA-1 + Ad4-PA-GPI-1Emergent BioSolutionsPhase 1
25
BioThraxEmergent BioSolutionsPhase 3
69
RaxibacumabEmergent BioSolutionsPhase 2/3
57
NP-015Emergent BioSolutionsPhase 1
25